Double maintains 2 strategies that include BCRX - BioCryst Pharmaceuticals, Inc.
Current Value
$8.831 Year Return
Current Value
$8.831 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 47.82% | $5.92B | 0.35% |
CPRJ | 46.20% | $50.86M | 0.69% |
PBE | 42.58% | $245.59M | 0.58% |
IBB | 41.95% | $6.33B | 0.45% |
PTH | 41.68% | $125.48M | 0.6% |
XPH | 40.98% | $164.02M | 0.35% |
IHE | 38.91% | $617.22M | 0.39% |
ARKG | 38.73% | $1.19B | 0.75% |
GNOM | 38.15% | $65.99M | 0.5% |
PINK | 36.79% | $142.29M | 0.5% |
IWC | 36.59% | $956.01M | 0.6% |
FXH | 36.56% | $1.04B | 0.62% |
IWM | 35.53% | $72.71B | 0.19% |
VTWO | 35.45% | $11.72B | 0.07% |
VHT | 35.22% | $16.89B | 0.09% |
FHLC | 35.01% | $2.78B | 0.084% |
SCHA | 34.89% | $18.63B | 0.04% |
XHE | 34.66% | $204.35M | 0.35% |
FYX | 34.65% | $960.72M | 0.6% |
DFAT | 34.61% | $11.15B | 0.28% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PRTA | 35.94% | $747.40M | -51.30% | 0.00% |
BX | 35.91% | $194.38B | +23.21% | 2.43% |
NVRI | 35.25% | $738.05M | +9.90% | 0.00% |
TFC | 34.84% | $61.68B | +27.88% | 3.37% |
TFSL | 33.78% | $3.86B | +2.92% | 8.19% |
COGT | 33.35% | $903.58M | -7.88% | 0.00% |
BEAM | 33.28% | $2.37B | -13.36% | 0.00% |
LINC | 33.27% | $550.89M | +74.30% | 0.00% |
AX | 33.22% | $4.02B | +27.67% | 0.00% |
MBWM | 33.21% | $795.63M | +26.51% | 2.88% |
HBNC | 33.20% | $757.58M | +35.81% | 3.68% |
CFB | 33.05% | $824.05M | +20.04% | 0.00% |
DNLI | 33.02% | $3.07B | +16.07% | 0.00% |
NFBK | 32.99% | $507.13M | +8.34% | 4.41% |
AROW | 32.72% | $454.30M | +9.57% | 4.10% |
VCEL | 32.48% | $2.80B | +15.07% | 0.00% |
FBK | 32.47% | $2.44B | +38.94% | 1.34% |
MARA | 32.45% | $5.74B | -37.42% | 0.00% |
TOWN | 32.20% | $2.78B | +31.52% | 2.70% |
UBSI | 32.17% | $5.17B | +6.84% | 3.85% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -17.86% | $277.56M | 1.43% |
DBA | -13.15% | $897.78M | 0.93% |
TAIL | -11.95% | $62.82M | 0.59% |
CLOA | -11.83% | $710.77M | 0.2% |
USCI | -11.71% | $215.20M | 1.07% |
XHLF | -10.95% | $1.07B | 0.03% |
KMLM | -10.90% | $327.00M | 0.9% |
DBE | -10.76% | $56.04M | 0.77% |
ULST | -10.54% | $558.12M | 0.2% |
DBO | -10.31% | $191.98M | 0.77% |
USL | -10.23% | $49.89M | 0.85% |
BNO | -10.08% | $94.01M | 1% |
VIXY | -9.58% | $195.31M | 0.85% |
USO | -9.21% | $1.12B | 0.6% |
OILK | -9.13% | $73.97M | 0.69% |
TPMN | -9.04% | $34.10M | 0.65% |
COMT | -8.70% | $745.89M | 0.48% |
USDU | -8.53% | $282.00M | 0.5% |
GSG | -7.88% | $1.08B | 0.75% |
BSMR | -7.80% | $219.88M | 0.18% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CATO | -0.02% | $72.29M | -49.71% | 14.29% |
IART | -0.02% | $1.87B | -45.79% | 0.00% |
MUX | 0.03% | $403.29M | +22.71% | 0.00% |
HCP | 0.05% | $7.02B | +40.59% | 0.00% |
SAM | -0.06% | $2.68B | -34.57% | 0.00% |
BE | -0.07% | $5.65B | +106.43% | 0.00% |
IRBT | -0.07% | $285.42M | -24.80% | 0.00% |
OKLO | 0.08% | $6.72B | +416.23% | 0.00% |
DMLP | -0.08% | $1.52B | +2.83% | 10.03% |
LICY | 0.11% | $29.96M | -74.75% | 0.00% |
ROL | 0.12% | $25.15B | +24.45% | 1.20% |
CNTY | -0.15% | $97.26M | +2.92% | 0.00% |
YY | 0.17% | $1.75B | +38.78% | 0.00% |
WEN | -0.18% | $3.01B | -22.27% | 6.73% |
SJM | -0.20% | $11.19B | -15.47% | 4.14% |
STNG | -0.21% | $2.37B | -36.54% | 3.49% |
TSN | -0.26% | $20.10B | +9.51% | 3.39% |
PAGP | -0.29% | $4.13B | +25.43% | 0.00% |
CART | -0.33% | $12.84B | +90.58% | 0.00% |
IRM | 0.34% | $27.95B | +37.76% | 2.89% |
Finnhub
RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2025 -- BioCryst Pharmaceuticals, Inc. today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees...
Finnhub
Presenter SpeechJessica Fye Welcome, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we are continuing the 43rd Annual House Conference today with BioCryst. First, you're
Yahoo
—ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025— —Company achieved operating profit in 2024 (not including stock-based compensation) and expects to approach quarterly EPS profitability/positive cash flow in 2H 2025— —New drug application planned in 2025 for ORLADEYO granules in children up to age 12; will address significant unmet need— —Pipeline advancing into patients with Netherton syn
Yahoo
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025, at 6:00 p.m. ET. Link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com. About BioCryst PharmaceuticalsBioCryst Pharmaceuticals is a global biotec
Yahoo
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
SeekingAlpha
BioCryst stock drops after Q3 results, but ORLADEYO's potential growth and solid financial health make it a strong buy for long-term investors.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FTSM | -0.02% | $6.21B | 0.45% |
NYF | 0.03% | $830.61M | 0.25% |
VGLT | -0.03% | $9.78B | 0.04% |
VGSH | 0.04% | $21.18B | 0.03% |
CMF | -0.05% | $3.86B | 0.08% |
UTEN | 0.06% | $153.88M | 0.15% |
AGZ | 0.07% | $689.92M | 0.2% |
TLT | -0.11% | $51.71B | 0.15% |
SPTL | -0.13% | $10.87B | 0.03% |
SPTI | 0.18% | $7.32B | 0.03% |
CMDY | 0.21% | $293.40M | 0.28% |
EDV | 0.22% | $3.71B | 0.05% |
TLH | 0.23% | $7.01B | 0.15% |
SCHQ | -0.23% | $725.50M | 0.03% |
UITB | 0.23% | $2.33B | 0.39% |
IBDT | 0.26% | $2.64B | 0.1% |
UTWO | -0.28% | $386.34M | 0.15% |
IBTM | 0.30% | $265.74M | 0.07% |
LQDW | -0.31% | $214.20M | 0.34% |
IBTH | 0.31% | $1.36B | 0.07% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
STG | -16.95% | $35.60M | -18.31% | 0.00% |
MNST | -9.23% | $48.16B | -11.84% | 0.00% |
HUSA | -8.80% | $22.27M | -3.40% | 0.00% |
SMC | -7.84% | $481.43M | +169.27% | 0.00% |
PULM | -7.58% | $27.36M | +307.07% | 0.00% |
SYPR | -7.01% | $47.20M | +6.49% | 0.00% |
SUN | -6.65% | $7.80B | -7.74% | 6.11% |
UUU | -6.16% | $4.91M | +50.71% | 0.00% |
CRCT | -6.06% | $1.24B | +16.41% | 3.45% |
CNP | -5.91% | $21.79B | +19.95% | 2.42% |
CL | -5.86% | $71.69B | +5.00% | 2.32% |
HEES | -5.80% | $3.20B | +55.33% | 1.25% |
DKL | -5.79% | $2.21B | -7.82% | 10.55% |
CME | -5.76% | $90.13B | +18.52% | 4.18% |
GIS | -5.72% | $32.82B | -5.93% | 3.97% |
PEP | -5.72% | $198.29B | -13.87% | 3.66% |
LUCK | -5.66% | $1.83B | -3.18% | 1.72% |
VHC | -5.30% | $33.93M | -1.31% | 0.00% |
LITB | -5.19% | $18.75M | -83.65% | 0.00% |
SE | -5.13% | $70.40B | +202.64% | 0.00% |